Jacobio Unveils Positive Clinical Data for KRAS G12C and SHP2 Inhibitor Combination in The Lancet Respiratory Medicine
I'm PortAI, I can summarize articles.
Jacobio Pharmaceuticals published positive Phase I/IIa clinical data for its KRAS G12C and SHP2 inhibitor combination in The Lancet Respiratory Medicine. The study, conducted in China, involved 171 patients and marks the first comprehensive clinical data of an all-oral combination in a major journal. This information was released via the Hong Kong Stock Exchange's Issuer Information Service.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments